BIIB vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 23, 2026
BIIB
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BIIB | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 18.4843 | 21.2314 | BIIB |
| PEG Ratio | 1.5653 | 106.1749 | BIIB |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 3.4% | 5.3% | GSK |
| Earnings Growth | -84.8% | -69.5% | GSK |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 42.3/100 | 53.7/100 | GSK |
| Profit Margin | 8.3% | 14.5% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | STRONG BUY | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BIIB
MarkupPrice above SMA50, rising 50-day trend (2.9% over 20 days), RSI 59
GSK
MarkupPrice above SMA50, rising 50-day trend (0.7% over 20 days), RSI 54
Fundamentals Snapshot
| Metric | BIIB | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 13.1 | 10.2 |
| Trailing P/E | 39.4 | 16.3 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | 0.8% | 0.7% |
| Operating Margin | 0.3% | 0.3% |
| EPS | 5.44 | 3.19 |
| Dividend Yield | — | 0.04% |